You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

  • Technology appraisal guidance
  • Reference number: TA218
  • Published:  23 March 2011
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Information for the public

  • Azacitidine for myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia (PDF 59 KB)

    Published:
    23 March 2011
  • Gwybodaeth i'r cyhoedd (Word 249 KB)

    Published:
    18 May 2011
Back to top